Skip to content
    ETON
    Earnings call· Jun 2026(Q2 FY26)

    Eton Pharmaceuticals Q2 FY26 earnings call ETON

    Aug 13, 2026 Source

    Executive summary

    Eton Pharmaceuticals Q2 FY26 — Record Revenue, Margin Expansion, and Strategic Portfolio Expansion

    Eton Pharmaceuticals delivered a strong second quarter, marked by record revenue and significant margin expansion driven by broad-based portfolio strength and the successful Hemangiol relaunch. The company strategically expanded its pediatric dermatology franchise through the acquisition of Impavido and licensing of ASN001, positioning itself for future growth without external financing. Management is focused on leveraging its commercial infrastructure to build leadership in rare disease therapies and expects continued momentum.

    Highlights

    5

    • Achieved record revenue of $37.6 million, representing 99% year-over-year growth.

    • Adjusted EBITDA increased to $16.2 million (43% of revenue) from $3.6 million (16% of revenue) in the prior year quarter.

    • Successfully relaunched Hemangiol, performing ahead of expectations with 95% patient transition by end of June.

    • Expanded portfolio through the acquisition of U.S. rights to Impavido and licensing of ASN001, a late-stage candidate with potential to become the largest product.

    • Received Fast Track designation for Amglidia and submitted a PAS for KendiV label expansion.

    Concerns

    2

    • Adjusted gross margin decreased to 73% from 75% in the prior year period, primarily due to higher Increlex sales outside the U.S. generating a negative gross margin.

    • R&D expenses decreased to $1 million from $3.7 million in the prior year, primarily due to a one-time FDA filing fee incurred in 2025, indicating a lower base for comparison.

    Guidance & targets

    8
    CategoryTargetConfidence
    Full-year revenue
    exceed $145 million
    high materiality
    High
    Full-year adjusted EBITDA margin
    exceed 35%
    high materiality
    High
    Longer-term adjusted EBITDA margin
    above 50%
    high materiality
    High
    Full-year adjusted gross margin
    exceed 70%
    medium materiality
    Medium
    Full-year R&D spending
    between $10 million and $14 million
    medium materiality
    Medium
    Annualized revenue run rate
    $200 million
    high materiality
    High
    Adjusted EBITDA margin
    50%
    high materiality
    High
    Annual revenue
    $500 million
    high materiality
    High

    Operational metrics

    21
    Adjusted EBITDA
    $16.2 millionup from $3.1 million (16% of revenue) in Q2 FY25
    Q2 FY26

    Compared to 16% of revenue in the prior year quarter.

    Adjusted gross profit
    $27.4 millionup from $14.1 million in Q2 FY25
    Q2 FY26

    Compared to 75% adjusted gross margin in the prior year period.

    Gross profit increase
    113%YoY
    Q2 FY26

    Primarily driven by higher product sales.

    R&D expenses
    $1 milliondown from $3.7 million in Q2 FY25
    Q2 FY26

    Decrease primarily due to Desmoda FDA filing fee incurred in 2025.

    G&A expenses
    $11.6 millionup from $9.7 million in Q2 FY25
    Q2 FY26

    Increase of 20% YoY.

    Adjusted G&A expense
    $10.2 millionup from $7.6 million in Q2 FY25
    Q2 FY26

    Increase primarily driven by additional headcount and $0.9 million in FDA fees.

    Non-GAAP net income
    $14.3 millionup from $1.5 million in Q2 FY25
    Q2 FY26

    Reported on a non-GAAP basis.

    Diluted EPS (non-GAAP)
    $0.43up from $0.03 in Q2 FY25
    Q2 FY26

    Reported on a non-GAAP basis.

    Cash on hand
    $26.8 million
    As of June 30, 2026

    After making a $3 million prepayment on outstanding debt.

    Debt prepayment
    $3 million
    Q2 FY26

    Made on outstanding debt.

    Valuation allowance
    $22 million
    As of June 30, 2026

    Against net deferred tax assets; release would result in a significant one-time non-cash income tax benefit.

    Hemangiol net price
    $8,000 to $10,000
    Per treated patient for a full course of therapy

    Best estimate, moves around month to month based on patient mix.

    Hemangiol patient conversion
    95%
    By end of June

    Transitioned to the new Eton Cares model, well ahead of expectations.

    Hemangiol annual patients
    exceeding 10,000
    Annually

    Expected volume after converting off-label users.

    ASN001 development cost
    $4 million
    Next 12 months

    Expected cost for the bioavailability bridging study.

    Desmoda peak sales
    $40 to $50 million
    Peak

    Reiterated from past guidance.

    Desmoda patient adds
    around 115%of targets
    First 5 months

    Very encouraging in terms of patient adds.

    Impavido annual contribution
    multiple millions of dollars
    Annually

    Expected contribution with very little upfront cost and resource distraction.

    Pediatric endocrinology active patients
    exceeding 600
    Current

    For Alkindi Sprinkle and KendiV adrenal franchise.

    KendiV target active patients
    1,000
    Target

    Goal for broader adoption after label expansion.

    Salesforce overlap
    over 90%
    Current

    Overlap among endocrinologists, supporting current sales force size.

    Industry KPIs

    3
    MetricValueDetails
    Peak sales guidance$40 to $50 millionUSD
    EPS revenue guidanceFY26 revenue >$145M; FY26 adjusted EBITDA margin >35%USD, %
    Business development capacity deal appetiteExpanded financial capacity

    Product announcements

    3
    ProductTypeDetails
    Hemangiollaunch
    Desmodalaunch
    Impavidolaunch

    Deals & partnerships

    2
    Not explicitly namedAcquisition of U.S. rights to Impavido

    Impavido is the only FDA-approved oral therapy for severe forms of leishmaniasis. Acquired with very little upfront payment.

    Not explicitly namedLicensing of ASN001$3 million

    ASN001 is a late-stage development candidate for infantile hemangiomas, supported by clinical data from a completed Phase 3 trial.

    Risks & headwinds

    3
    Negative gross margin from international Increlex salesQ2 FY26

    Higher Increlex sales outside the U.S. generate a negative gross margin.

    Rebate dynamics impacting Hemangiol's gross-to-netOngoing

    ASN001 is expected to have more favorable net pricing economics because it would not be subject to certain rebate dynamics that weigh on Hemangiol's gross-to-net.

    Mitigation: Introduction of ASN001 with more favorable net pricing.

    Valuation allowance against net deferred tax assetsOngoing

    Approximately $22 million as of June 30, 2026.

    Mitigation: If the company continues to execute against its current forecast and exits the cumulative loss position, the valuation allowance may be released in H2 2026, resulting in a one-time non-cash income tax benefit.

    What to watch in Q3 FY26

    5

    ET-700 pilot study initial results

    Next month or two
    CurrentStudy ongoing
    TargetInitial results available

    Why it matters

    Will determine if the study supports initiation of a pivotal clinical study, impacting the long-term growth opportunity in Wilson Disease.

    We expect initial results in the next month or 2 with the full study report expected by the end of the year.

    Q&A highlights

    8

    What is the net realized price for Hemangiol, how does it compare to previous expectations, and what is the current patient volume and retention rate after the transition?

    Management reaffirmed the $8,000-$10,000 net price expectation for Hemangiol, noting it fluctuates but is stabilizing. They confirmed 95% patient conversion by end of June, now focusing on growing volume by converting off-label users.

    “On the net pricing, we're still sticking with that $8,000 to $10,000 net price. On average, we think that's going to be our best estimate.”

    asked by Chase Knickerbocker · answered by David Krempa

    2 min read6 chapters

    Detailed Narrative

    01

    Hemangiol Relaunch Success and Market Opportunity

    Eton successfully relaunched Hemangiol on May 1st, achieving approximately 95% patient transition to its new Eton Cares access model by the end of June, significantly ahead of the 3-4 month expectation. This new model, featuring a $0 copay program, aims to remove historical barriers to adoption and encourage the use of FDA-approved Hemangiol over off-label adult formulations for infantile hemangioma. The company believes this strategy will drive continued growth, with annual patients expected to exceed 10,000.

    02

    Strategic Expansion in Pediatric Dermatology with ASN001

    The company expanded its pediatric dermatology franchise by licensing ASN001, a late-stage development candidate for infantile hemangiomas. ASN001 targets moderate cases, a patient population estimated to be 2-3 times larger than Hemangiol, and is expected to complement Hemangiol rather than compete. Eton plans to leverage its existing commercial infrastructure and customer relationships, anticipating ASN001 will have more favorable net pricing economics and become the largest product in its portfolio upon its potential 2028 launch.

    03

    Disciplined Capital Allocation and Business Model Strength

    Eton highlighted its ability to identify and execute highly strategic, potentially transformational transactions, such as the Impavido acquisition and ASN001 licensing, without external financing and while expanding profitability. This demonstrates the strength of its business model and disciplined approach to capital allocation. The company aims to continue pursuing value-creating business development opportunities that accelerate revenue and earnings growth, leveraging its proven commercial track record in rare diseases.

    04

    Pediatric Endocrinology Portfolio Momentum

    The adrenal franchise, including Alkindi Sprinkle and KendiV, continues to show reliable growth, now serving over 600 active patients. A Prior Approval Supplement (PAS) was submitted for KendiV to expand its label to patients under 5, with approval expected in H1 2027. The launch of Desmoda has been encouraging, resonating with clinicians due to its precise dosing capabilities, and is helping expand commercial reach to adult endocrinologists. Increlex also delivered strong year-over-year revenue growth, with a label harmonization study underway.

    05

    Pipeline Progress and Regulatory Milestones

    Amglidia, for neonatal diabetes, received Fast Track designation, and its bioavailability study was initiated in August 2026, with NDA submission planned by year-end for potential 2027 approval. The ET-700 pilot study for Wilson Disease is ongoing, with initial results expected in the next 1-2 months, potentially supporting a pivotal clinical study in early 2027. The ASN001 bioavailability bridging study, the final development requirement, is set to begin in the coming weeks, leading to an NDA submission in H2 2027.

    06

    Impavido Acquisition and Commercial Strategy

    Eton acquired U.S. distribution rights for Impavido, the only FDA-approved oral therapy for severe leishmaniasis. The company plans to begin distributing the product in late September, leveraging its specialized sales force and Eton Cares program to expand access. This approach contrasts with the product's previous single-person distributor model, aiming to provide meaningful value to prescribers and patients through centralized support, $0 copay, and Medicaid coverage.

    AI-generated summary of the company’s earnings call. Not investment advice.